Study 3 of 20Exenatide literatureLancet (London, England) · Phase 3Top journal2026
Expression of Concern: Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.
Not reported in abstract.
Where it sits
this study against the rest of the exenatide corpus2
Preclinical · this one
11
Observational
0
Open-label
2
Randomised
5
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.00). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
Phase 32026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Exenatide corpus
BPrescription Sequence Symmetry Analysis of Glucagon-Like Peptide-1 Receptor Agonists and Neuropsychiatric Conditions.Clinical pharmacology and therapeutics · 2026 · n=2033 · aSR: 0.85; 95% CI: 0.76-0.94 for antidepressants initiationHumanCDevelopment of Chondroitin Sulfate ‑ Stabilized PLGA Microspheres of Exenatide via Polarity Gradient Extraction.Pharmaceutical development and technology · 2026 · Drug loading up to 4.7% w/w.AnimalBGlucagon-like Peptide-1 Receptor Agonist-Associated Injection Site and Dermatologic Reactions.Clinics in dermatology · 2026 · n=442567 · 53.1% of skin and injection-site reports for exenatide.reviewCAcute glucagon-like peptide-1 receptor agonist, semaglutide, attenuates cue-, drug-, and stress-induced fentanyl seeking in male Sprague-Dawley rats.Behavioural pharmacology · 2026 · All doses of semaglutide fully prevented drug- and stress-induced reinstatement of fentanyl seeking.AnimalDGLP-1 Receptor Agonists and Endoscopy: Understanding Gastric Stasis, Aspiration Risk, and Contemporary Peri-Procedural Guidance.Chronic diseases and translational medicine · 2026 · Aspiration rates during colonoscopy are approximately 0.01%-0.05%.reviewBMulti-Database Pharmacovigilance Analysis of Gastroesophageal Reflux Disease Associated with GLP-1 Receptor Agonists: A Cross-National Signal Validation Study.Gut and liver · 2026 · n=260417 · Exenatide showed an inverse association in FAERS (ROR, 0.60; 95% CI, 0.46 to 0.77).Human